1. Nasal Nitric Oxide Measurement in Primary Ciliary Dyskinesia. A Technical Paper on Standardized Testing Protocols
- Author
-
Sharon D. Dell, Nadzeya Marozkina, Margaret W. Leigh, Milan J. Hazucha, Michele Manion, Adam J. Shapiro, Benjamin Gaston, and Michael Glenn O’Connor
- Subjects
Pulmonary and Respiratory Medicine ,Operating procedures ,Population ,Diagnostic accuracy ,Nitric Oxide ,Sensitivity and Specificity ,Nitric oxide ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Technical Statement ,otorhinolaryngologic diseases ,medicine ,Humans ,030212 general & internal medicine ,education ,Societies, Medical ,Primary ciliary dyskinesia ,education.field_of_study ,Kartagener Syndrome ,business.industry ,Patient Selection ,Diagnostic test ,medicine.disease ,United States ,Nitric Oxide Measurement ,Breath Tests ,030228 respiratory system ,chemistry ,Anesthesia ,Nasal Cavity ,business - Abstract
Nasal nitric oxide concentrations are extremely low in primary ciliary dyskinesia (PCD), and measurement of this nasal gas is recommended as a PCD diagnostic test in cooperative patients aged 5 years and older. However, nasal nitric oxide measurements must be performed with chemiluminescence analyzers using a standardized protocol to ensure proper results, because nasal nitric oxide values can be influenced by various internal and external factors. Repeat nasal nitric oxide testing on separate visits is required to ensure that low diagnostic values are persistent and consistent with PCD. This technical paper presents the standard operating procedures for nasal nitric oxide measurement used by the PCD Foundation Clinical and Research Centers Network at various specialty centers across North America. Adherence to this document ensures reliable nasal nitric oxide testing and high diagnostic accuracy when employed in a population with appropriate clinical phenotypes for PCD.
- Published
- 2020
- Full Text
- View/download PDF